文献速递疼痛医学区域麻醉与超声

NGF/TrKA通路通过增加δ-阿片受体膜水平增强骨癌痛小鼠镇痛

Nerve Growth Factor/Tyrosine Kinase A Receptor Pathway Enhances Analgesia in an Experimental Mouse Model of Bone Cancer Pain by Increasing Membrane Levels of δ-Opioid Receptors.
PubMed 文献 · Anesthesiology · 2024-01-01

该研究在小鼠骨癌痛模型中探究NGF/TrKA信号对膜相关δ-阿片受体(mDOR)表达的调控。结果发现BCP小鼠mDOR和NGF表达升高,DOR激动剂Del2提高痛阈并降低脊髓兴奋性突触传递,且NGF通过TrKA信号增强mDOR表达。结论提示mDOR激活产生的镇痛依赖于NGF/TrKA通路上调mDOR水平。

要点

  • 骨癌痛小鼠脊髓mDOR和NGF表达均升高,且NGF通过TrKA信号增强mDOR表达。
  • DOR激动剂Del2可提高骨癌痛小鼠痛阈并降低脊髓II层外侧神经元mEPSC频率。
  • mDOR激活的镇痛效应依赖于NGF/TrKA通路对mDOR膜水平的正向调控。

核心结论

  • mDOR激活在骨癌痛条件下产生镇痛,该效应依赖于NGF/TrKA通路上调mDOR水平。

研究设计与样本

  • 实验性小鼠骨癌痛模型研究,将Lewis肺癌细胞接种至成年C57BL/6J雌雄小鼠股骨髓腔诱导BCP。
  • 采用von Frey和Hargreaves试验评估痛行为,生化分析检测脊髓背角蛋白表达,并记录微小兴奋性突触电流。

主要发现

  • BCP小鼠mDOR表达较假手术组升高(0.18 ± 0.01 g vs. 0.13 ± 0.01 g,n = 4,P < 0.001)。
  • DOR激动剂Del2较溶媒提高痛阈(中位数[25th, 75th百分位]:1.00 [0.60, 1.40] g vs. 0.40 [0.16, 0.45] g,n = 10,P = 0.001)。
  • Del2较基线降低II层外侧神经元mEPSC频率(2.21 ± 0.81 Hz vs. 2.43 ± 0.90 Hz,n = 12,P < 0.001)。
  • BCP小鼠NGF表达较假手术组升高(0.36 ± 0.03 vs. 0.16 ± 0.02,n = 4,P < 0.001),且升高的NGF通过TrKA信号与mDOR表达增强相关。

临床怎么用

  • 骨癌痛状态下mDOR表达上调,提示δ-阿片受体激动剂可能具有镇痛潜力。
  • NGF/TrKA通路对mDOR膜水平的调控可能是骨癌痛镇痛的潜在靶点。

局限性

  • 研究为小鼠实验模型,结论向临床转化需进一步验证。
  • 原文未报告其他局限性信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The role of nerve growth factor (NGF)/tyrosine kinase A receptor (TrKA) signaling, which is activated in a variety of pain states, in regulating membrane-associated δ-opioid receptor (mDOR) expression is poorly understood. The hypothesis was that elevated NGF in bone cancer tumors could upregulate mDOR expression in spinal cord neurons and that mDOR agonism might alleviate bone cancer pain. METHODS: Bone cancer pain (BCP) was induced by inoculating Lewis lung carcinoma cells into the femoral marrow cavity of adult C57BL/6J mice of both sexes. Nociceptive behaviors were evaluated by the von Frey and Hargreaves tests. Protein expression in the spinal dorsal horn of animals was measured by biochemical analyses, and excitatory synaptic transmission was recorded in miniature excitatory synaptic currents. RESULTS: The authors found that mDOR expression was increased in BCP mice (BCP vs. sham, mean ± SD: 0.18 ± 0.01 g vs. mean ± SD: 0.13 ± 0.01 g, n = 4, P < 0.001) and that administration of the DOR agonist deltorphin 2 (Del2) increased nociceptive thresholds (Del2 vs. vehicle, median [25th, 75th percentiles]: 1.00 [0.60, 1.40] g vs. median [25th, 75th percentiles]: 0.40 [0.16, 0.45] g, n = 10, P = 0.001) and reduced miniature excitatory synaptic current frequency in lamina II outer neurons (Del2 vs. baseline, mean ± SD: 2.21 ± 0.81 Hz vs. mean ± SD: 2.43 ± 0.90 Hz, n = 12, P < 0.001). Additionally, NGF expression was increased in BCP mice (BCP vs. sham, mean ± SD: 0.36 ± 0.03 vs. mean ± SD: 0.16 ± 0.02, n = 4, P < 0.001), and elevated NGF was associated with enhanced mDOR expression via TrKA signaling. CONCLUSIONS: Activation of mDOR produces analgesia that is dependent on the upregulation of the NGF/TrKA pathway by increasing mDOR levels under conditions of BCP in mice.

来源:Anesthesiology,查看原文。版权归原作者所有。

引用

  1. Kan BF, Liu XY, Han MM, et al. Nerve Growth Factor/Tyrosine Kinase A Receptor Pathway Enhances Analgesia in an Experimental Mouse Model of Bone Cancer Pain by Increasing Membrane Levels of δ-Opioid Receptors. Anesthesiology. 2024. PMID: 38118180. doi:10.1097/ALN.0000000000004880

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。